ESCMID*  ||| S:0 E:8 ||| NNP
guideline  ||| S:8 E:18 ||| NN
for  ||| S:18 E:22 ||| IN
the  ||| S:22 E:26 ||| DT
diagnosis  ||| S:26 E:36 ||| NN
and  ||| S:36 E:40 ||| CC
management  ||| S:40 E:51 ||| NN
of  ||| S:51 E:54 ||| IN
Candida  ||| S:54 E:62 ||| NNP
diseases  ||| S:62 E:71 ||| VBD
2012 ||| S:71 E:75 ||| CD
:  ||| S:75 E:77 ||| :
adults  ||| S:77 E:84 ||| NNS
with  ||| S:84 E:89 ||| IN
haematological  ||| S:89 E:104 ||| JJ
malignancies  ||| S:104 E:117 ||| NN
and  ||| S:117 E:121 ||| CC
after  ||| S:121 E:127 ||| IN
haematopoietic  ||| S:127 E:142 ||| JJ
stem  ||| S:142 E:147 ||| NN
cell  ||| S:147 E:152 ||| NN
transplantation  ||| S:152 E:168 ||| NN
( ||| S:168 E:169 ||| -LRB-
HCT ||| S:169 E:172 ||| NNP
)  ||| S:172 E:174 ||| -RRB-
Fungal  ||| S:174 E:181 ||| NNP
diseases  ||| S:181 E:190 ||| NNS
still  ||| S:190 E:196 ||| RB
play  ||| S:196 E:201 ||| VB
a  ||| S:201 E:203 ||| DT
major  ||| S:203 E:209 ||| JJ
role  ||| S:209 E:214 ||| NN
in  ||| S:214 E:217 ||| IN
morbidity  ||| S:217 E:227 ||| NN
and  ||| S:227 E:231 ||| CC
mortality  ||| S:231 E:241 ||| NN
in  ||| S:241 E:244 ||| IN
patients  ||| S:244 E:253 ||| NNS
with  ||| S:253 E:258 ||| IN
haematological  ||| S:258 E:273 ||| JJ
malignancies ||| S:273 E:285 ||| NN
,  ||| S:285 E:287 ||| ,
including  ||| S:287 E:297 ||| VBG
those  ||| S:297 E:303 ||| DT
undergoing  ||| S:303 E:314 ||| JJ
haematopoietic  ||| S:314 E:329 ||| NNS
stem  ||| S:329 E:334 ||| VBP
cell  ||| S:334 E:339 ||| NN
transplantation ||| S:339 E:354 ||| NN
.  ||| S:354 E:356 ||| .
Although  ||| S:356 E:365 ||| IN
Aspergillus  ||| S:365 E:377 ||| NNP
and  ||| S:377 E:381 ||| CC
other  ||| S:381 E:387 ||| JJ
filamentous  ||| S:387 E:399 ||| JJ
fungal  ||| S:399 E:406 ||| JJ
diseases  ||| S:406 E:415 ||| NNS
remain  ||| S:415 E:422 ||| VBP
a  ||| S:422 E:424 ||| DT
major  ||| S:424 E:430 ||| JJ
concern ||| S:430 E:437 ||| NN
,  ||| S:437 E:439 ||| ,
Candida  ||| S:439 E:447 ||| NNP
infections  ||| S:447 E:458 ||| NNS
are  ||| S:458 E:462 ||| VBP
still  ||| S:462 E:468 ||| RB
a  ||| S:468 E:470 ||| DT
major  ||| S:470 E:476 ||| JJ
cause  ||| S:476 E:482 ||| NN
of  ||| S:482 E:485 ||| IN
mortality ||| S:485 E:494 ||| NN
.  ||| S:494 E:496 ||| .
This  ||| S:496 E:501 ||| DT
part  ||| S:501 E:506 ||| NN
of  ||| S:506 E:509 ||| IN
the  ||| S:509 E:513 ||| DT
ESCMID  ||| S:513 E:520 ||| NNP
guidelines  ||| S:520 E:531 ||| NNS
focuses  ||| S:531 E:539 ||| VBZ
on  ||| S:539 E:542 ||| IN
this  ||| S:542 E:547 ||| DT
patient  ||| S:547 E:555 ||| JJ
population  ||| S:555 E:566 ||| NN
and  ||| S:566 E:570 ||| CC
reviews  ||| S:570 E:578 ||| NNS
pertaining  ||| S:578 E:589 ||| VBP
to  ||| S:589 E:592 ||| TO
prophylaxis ||| S:592 E:603 ||| VB
,  ||| S:603 E:605 ||| ,
empirical ||| S:605 E:614 ||| CD
/ ||| S:614 E:615 ||| CD
pre-emptive  ||| S:615 E:627 ||| JJ
and  ||| S:627 E:631 ||| CC
targeted  ||| S:631 E:640 ||| JJ
therapy  ||| S:640 E:648 ||| NN
of  ||| S:648 E:651 ||| IN
Candida  ||| S:651 E:659 ||| NNP
diseases ||| S:659 E:667 ||| NNS
.  ||| S:667 E:669 ||| .
Anti-Candida  ||| S:669 E:682 ||| JJ
prophylaxis  ||| S:682 E:694 ||| NN
is  ||| S:694 E:697 ||| VBZ
only  ||| S:697 E:702 ||| RB
recommended  ||| S:702 E:714 ||| VBN
for  ||| S:714 E:718 ||| IN
patients  ||| S:718 E:727 ||| NNS
receiving  ||| S:727 E:737 ||| VBG
allogeneic  ||| S:737 E:748 ||| JJ
stem  ||| S:748 E:753 ||| NN
cell  ||| S:753 E:758 ||| NN
transplantation ||| S:758 E:773 ||| NN
.  ||| S:773 E:775 ||| .
The  ||| S:775 E:779 ||| DT
authors  ||| S:779 E:787 ||| NNS
recognize  ||| S:787 E:797 ||| VBP
that  ||| S:797 E:802 ||| IN
the  ||| S:802 E:806 ||| DT
recommendations  ||| S:806 E:822 ||| NNS
would  ||| S:822 E:828 ||| MD
have  ||| S:828 E:833 ||| VB
most  ||| S:833 E:838 ||| RBS
likely  ||| S:838 E:845 ||| RB
been  ||| S:845 E:850 ||| VBN
different  ||| S:850 E:860 ||| JJ
if  ||| S:860 E:863 ||| IN
the  ||| S:863 E:867 ||| DT
purpose  ||| S:867 E:875 ||| NN
would  ||| S:875 E:881 ||| MD
have  ||| S:881 E:886 ||| VB
been  ||| S:886 E:891 ||| VBN
prevention  ||| S:891 E:902 ||| NN
of  ||| S:902 E:905 ||| IN
all  ||| S:905 E:909 ||| DT
fungal  ||| S:909 E:916 ||| JJ
infections  ||| S:916 E:927 ||| NNS
( ||| S:927 E:928 ||| -LRB-
e.g.  ||| S:928 E:933 ||| FW
aspergillosis ||| S:933 E:946 ||| FW
) ||| S:946 E:947 ||| -RRB-
.  ||| S:947 E:949 ||| .
In  ||| S:949 E:952 ||| IN
targeted  ||| S:952 E:961 ||| JJ
treatment  ||| S:961 E:971 ||| NN
of  ||| S:971 E:974 ||| IN
candidaemia ||| S:974 E:985 ||| NN
,  ||| S:985 E:987 ||| ,
recommendations  ||| S:987 E:1003 ||| NNS
for  ||| S:1003 E:1007 ||| IN
treatment  ||| S:1007 E:1017 ||| NN
are  ||| S:1017 E:1021 ||| VBP
available  ||| S:1021 E:1031 ||| JJ
for  ||| S:1031 E:1035 ||| IN
all  ||| S:1035 E:1039 ||| DT
echinocandins ||| S:1039 E:1052 ||| NN
,  ||| S:1052 E:1054 ||| ,
that  ||| S:1054 E:1059 ||| WDT
is  ||| S:1059 E:1062 ||| VBZ
anidulafungin  ||| S:1062 E:1076 ||| JJ
( ||| S:1076 E:1077 ||| -LRB-
AI ||| S:1077 E:1079 ||| NNP
) ||| S:1079 E:1080 ||| -RRB-
,  ||| S:1080 E:1082 ||| ,
caspofungin  ||| S:1082 E:1094 ||| NNS
( ||| S:1094 E:1095 ||| -LRB-
AI ||| S:1095 E:1097 ||| NNP
)  ||| S:1097 E:1099 ||| -RRB-
and  ||| S:1099 E:1103 ||| CC
micafungin  ||| S:1103 E:1114 ||| NNS
( ||| S:1114 E:1115 ||| -LRB-
AI ||| S:1115 E:1117 ||| NNP
) ||| S:1117 E:1118 ||| -RRB-
,  ||| S:1118 E:1120 ||| ,
although  ||| S:1120 E:1129 ||| IN
a  ||| S:1129 E:1131 ||| DT
warning  ||| S:1131 E:1139 ||| NN
for  ||| S:1139 E:1143 ||| IN
resistance  ||| S:1143 E:1154 ||| NN
is  ||| S:1154 E:1157 ||| VBZ
expressed ||| S:1157 E:1166 ||| VBN
.  ||| S:1166 E:1168 ||| .
Liposomal  ||| S:1168 E:1178 ||| NNP
amphotericin  ||| S:1178 E:1191 ||| VBD
B  ||| S:1191 E:1193 ||| NNP
received  ||| S:1193 E:1202 ||| VBD
a  ||| S:1202 E:1204 ||| DT
BI  ||| S:1204 E:1207 ||| NNP
recommendation  ||| S:1207 E:1222 ||| NN
due  ||| S:1222 E:1226 ||| JJ
to  ||| S:1226 E:1229 ||| TO
higher  ||| S:1229 E:1236 ||| JJR
number  ||| S:1236 E:1243 ||| NN
of  ||| S:1243 E:1246 ||| IN
reported  ||| S:1246 E:1255 ||| VBN
adverse  ||| S:1255 E:1263 ||| JJ
events  ||| S:1263 E:1270 ||| NNS
in  ||| S:1270 E:1273 ||| IN
the  ||| S:1273 E:1277 ||| DT
trials ||| S:1277 E:1283 ||| NNS
.  ||| S:1283 E:1285 ||| .
Amphotericin  ||| S:1285 E:1298 ||| NNP
B  ||| S:1298 E:1300 ||| NNP
deoxycholate  ||| S:1300 E:1313 ||| NN
should  ||| S:1313 E:1320 ||| MD
not  ||| S:1320 E:1324 ||| RB
be  ||| S:1324 E:1327 ||| VB
used  ||| S:1327 E:1332 ||| VBN
( ||| S:1332 E:1333 ||| -LRB-
DII ||| S:1333 E:1336 ||| NNP
) ||| S:1336 E:1337 ||| -RRB-
;  ||| S:1337 E:1339 ||| :
and  ||| S:1339 E:1343 ||| CC
fluconazole  ||| S:1343 E:1355 ||| NNS
was  ||| S:1355 E:1359 ||| VBD
rated  ||| S:1359 E:1365 ||| VBN
CI  ||| S:1365 E:1368 ||| NNP
because  ||| S:1368 E:1376 ||| IN
of  ||| S:1376 E:1379 ||| IN
a  ||| S:1379 E:1381 ||| DT
change  ||| S:1381 E:1388 ||| NN
in  ||| S:1388 E:1391 ||| IN
epidemiology  ||| S:1391 E:1404 ||| NN
in  ||| S:1404 E:1407 ||| IN
some  ||| S:1407 E:1412 ||| DT
areas  ||| S:1412 E:1418 ||| NNS
in  ||| S:1418 E:1421 ||| IN
Europe ||| S:1421 E:1427 ||| NNP
.  ||| S:1427 E:1429 ||| .
Removal  ||| S:1429 E:1437 ||| NN
of  ||| S:1437 E:1440 ||| IN
central  ||| S:1440 E:1448 ||| JJ
venous  ||| S:1448 E:1455 ||| JJ
catheters  ||| S:1455 E:1465 ||| NN
is  ||| S:1465 E:1468 ||| VBZ
recommended  ||| S:1468 E:1480 ||| VBN
during  ||| S:1480 E:1487 ||| IN
candidaemia  ||| S:1487 E:1499 ||| NN
but  ||| S:1499 E:1503 ||| CC
if  ||| S:1503 E:1506 ||| IN
catheter  ||| S:1506 E:1515 ||| JJ
retention  ||| S:1515 E:1525 ||| NN
is  ||| S:1525 E:1528 ||| VBZ
a  ||| S:1528 E:1530 ||| DT
clinical  ||| S:1530 E:1539 ||| JJ
necessity ||| S:1539 E:1548 ||| NN
,  ||| S:1548 E:1550 ||| ,
treatment  ||| S:1550 E:1560 ||| NN
with  ||| S:1560 E:1565 ||| IN
an  ||| S:1565 E:1568 ||| DT
echinocandin  ||| S:1568 E:1581 ||| NN
is  ||| S:1581 E:1584 ||| VBZ
an  ||| S:1584 E:1587 ||| DT
option  ||| S:1587 E:1594 ||| NN
( ||| S:1594 E:1595 ||| -LRB-
CII ||| S:1595 E:1598 ||| NNP
( ||| S:1598 E:1599 ||| -LRB-
t ||| S:1599 E:1600 ||| LS
)  ||| S:1600 E:1602 ||| -RRB-
) ||| S:1602 E:1603 ||| -RRB-
.  ||| S:1603 E:1605 ||| .
In  ||| S:1605 E:1608 ||| IN
chronic  ||| S:1608 E:1616 ||| JJ
disseminated  ||| S:1616 E:1629 ||| JJ
candidiasis  ||| S:1629 E:1641 ||| JJ
therapy ||| S:1641 E:1648 ||| NN
,  ||| S:1648 E:1650 ||| ,
recommendations  ||| S:1650 E:1666 ||| NNS
are  ||| S:1666 E:1670 ||| VBP
liposomal  ||| S:1670 E:1680 ||| JJ
amphotericin  ||| S:1680 E:1693 ||| JJ
B  ||| S:1693 E:1695 ||| NN
for  ||| S:1695 E:1699 ||| IN
8  ||| S:1699 E:1701 ||| CD
weeks  ||| S:1701 E:1707 ||| NNS
( ||| S:1707 E:1708 ||| -LRB-
AIII ||| S:1708 E:1712 ||| NNP
) ||| S:1712 E:1713 ||| -RRB-
,  ||| S:1713 E:1715 ||| ,
fluconazole  ||| S:1715 E:1727 ||| VBG
for  ||| S:1727 E:1731 ||| IN
> ||| S:1731 E:1732 ||| CD
3  ||| S:1732 E:1734 ||| CD
months  ||| S:1734 E:1741 ||| NNS
or  ||| S:1741 E:1744 ||| CC
other  ||| S:1744 E:1750 ||| JJ
azoles  ||| S:1750 E:1757 ||| NNS
( ||| S:1757 E:1758 ||| -LRB-
BIII ||| S:1758 E:1762 ||| NNP
) ||| S:1762 E:1763 ||| -RRB-
.  ||| S:1763 E:1765 ||| .
Granulocyte  ||| S:1765 E:1777 ||| JJ
transfusions  ||| S:1777 E:1790 ||| NNS
are  ||| S:1790 E:1794 ||| VBP
only  ||| S:1794 E:1799 ||| RB
an  ||| S:1799 E:1802 ||| DT
option  ||| S:1802 E:1809 ||| NN
in  ||| S:1809 E:1812 ||| IN
desperate  ||| S:1812 E:1822 ||| JJ
cases  ||| S:1822 E:1828 ||| NNS
of  ||| S:1828 E:1831 ||| IN
patients  ||| S:1831 E:1840 ||| NNS
with  ||| S:1840 E:1845 ||| IN
Candida  ||| S:1845 E:1853 ||| NNP
disease  ||| S:1853 E:1861 ||| NN
and  ||| S:1861 E:1865 ||| CC
neutropenia  ||| S:1865 E:1877 ||| NNS
( ||| S:1877 E:1878 ||| -LRB-
CIII ||| S:1878 E:1882 ||| NNP
) ||| S:1882 E:1883 ||| -RRB-
.  ||| S:1883 E:1885 ||| .
